StickIt Technologies Inc. Announces Leadership Changes and Corporate Milestones

VANCOUVER, BC September 17, 2026 — Leads & Copy — StickIt Technologies Inc. (CSE: STKT), a developer and patent holder of proprietary cannabinoid and plant extract delivery technologies, today provided a comprehensive corporate update detailing leadership changes, recent financial transactions including loan acquisitions and private placements, and developments across its international intellectual property portfolio.

Effective July 10, 2026, Dr. Adi Zuloff-Shani has been appointed Chief Executive Officer, succeeding Eli Ben-Haroosh, who resigned on April 1, 2026. Dr. Zuloff-Shani brings extensive executive leadership, biotechnology expertise, and operational acumen to drive StickIt's global joint venture strategy and commercial distribution. Dr. Zuloff-Shani is a biomedical executive and immunologist with over two decades of experience leading therapeutic research and development across biotech and pharmaceutical companies. She also serves as CEO of Clearmind Medicine (NASDAQ: CMND), overseeing the development of non-hallucinogenic psychedelic-derived treatments for mental health and addiction disorders.

Additionally, effective July 10, 2026, Mr. Gabriel Kabazo and Mr. Nir Eliyahu joined the Board of Directors as independent, non-executive directors. Mr. Kabazo is a finance and operations professional with over 25 years of experience in accounting, financing, and IT operations. He currently serves as Chief Financial Officer or Chief Executive Officer of several public companies listed on the TSX Venture Exchange, Canadian Securities Exchange, and U.S. markets. Mr. Eliyahu is a private business owner with nine years of experience in distribution channels and online sales, specializing in building distribution channels for B2B and B2C products, brand development, marketing, sales strategies, and a training platform. He holds a BSc degree in Electrical Engineering from the University of Ariel.

"We are thrilled to welcome Dr. Adi Zuloff-Shani as our CEO and expand our Board with seasoned independent directors like Mr. Kabazo and Mr. Eliyahu," stated Ohad David, Chair of the Board. "These appointments mark a critical milestone in sharpening our strategic execution, enhancing board independence, and driving sustainable shareholder value."

StickIt has also completed key corporate recapitalization and financing milestones. In connection with corporate reorganization initiatives, the Company executed transactions under a letter of intent with Capitalink Ltd., under which Capitalink acquired rights to outstanding debt amounts previously owed by the Company to corporate insiders totaling approximately $617,000 for a restructured consideration of $380,000. This loan assignment alleviates short-term liability pressures and simplifies the Company's debt structure. The acquisition of the debt was made directly between Mr. Eli Ben Haroosh and Mr. Asher Holzer on one side and Capitalink, and the Company was not a party to this agreement.

Furthering its financial stabilization plan, StickIt closed a non-brokered private placement offering of 28,884,000 units at CAD $0.025 per unit, raising aggregate gross proceeds of CAD $722,100. Each unit consists of one common share and one transferable common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at an exercise price of CAD $0.025 for a period of 36 months from closing. The Company also completed a share consolidation (1 post-consolidation share for 5 pre-consolidation shares). Net proceeds have been allocated to working capital, joint-venture setup costs, raw material procurement, and scaling the commercial production of its flagship "Cannabis Sticks" product lines.

StickIt continues to enforce and broaden its competitive advantage through a robust global intellectual property strategy centered on its novel, patent-protected delivery vehicles for therapeutic compounds, plant extracts, and cannabinoid delivery systems. The Company's core intellectual property encompasses its proprietary "Plant Extracts and Therapeutic Compounds in Smoking Utensils and in Honey Complexes," which includes methods and utensils for administering plant extracts at controlled amounts via smoking, as well as providing complexes of honey and plant extracts. The United States has granted US Patent (US11582996 B2) covering therapeutic plant extract delivery devices and specialized smoking utensil inserts.

Stickit's operating model involves establishing joint ventures in countries where recreational cannabis is permitted. Each licensee/joint venture partner will establish a production facility where they will add the cannabis content to sticks produced and supplied by Stickit. StickIt is expected to provide the joint venture with the know-how required to manufacture the finished product. The licensee/joint venture partner will produce the finished product, adding cannabis to the raw materials provided by StickIt, and will sell them either directly to points of sale or through distributors. The licensee is expected to pay a setup fee by investing the funds necessary to set up the local production facility. Each licensee will have exclusive rights to produce and market Stickit products in their designated territory.

StickIt Technologies Inc. is a technology company focused on inventing, patenting, and commercializing advanced delivery systems for cannabinoids, plant extracts, and therapeutic ingredients. StickIt's primary assets consist of a US granted patent protecting methods and utensils for administrating plant extracts at controlled amount via smoking as well as for providing complexed of honey and plant extracts.

Source: StickIt Technologies Inc.